Double-blind Randomised Phase I/IIb Study
Patients will receive CT-P6 or Herceptin.
Interventional
Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
PK parameter
months
No
Investigational Site
Principal Investigator
Samsung Medical Center
Korea: Food and Drug Administration
CT-P6/1.1
NCT01084863
January 2010
June 2013
Name | Location |
---|